These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 35681606)

  • 1. Emerging Blood-Based Biomarkers for Predicting Immunotherapy Response in NSCLC.
    Oitabén A; Fonseca P; Villanueva MJ; García-Benito C; López-López A; Garrido-Fernández A; González-Ojea C; Juaneda-Magdalena L; Lázaro ME; Martínez-Fernández M
    Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade.
    Tsai YT; Schlom J; Donahue RN
    J Exp Clin Cancer Res; 2024 Mar; 43(1):82. PubMed ID: 38493133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applications of Circulating Tumor DNA in Immune Checkpoint Inhibition: Emerging Roles and Future Perspectives.
    Lu C; Zhang YC; Chen ZH; Zhou Q; Wu YL
    Front Oncol; 2022; 12():836891. PubMed ID: 35359372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy.
    Honrubia-Peris B; Garde-Noguera J; García-Sánchez J; Piera-Molons N; Llombart-Cussac A; Fernández-Murga ML
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors.
    Nie W; Wang ZJ; Zhang K; Li B; Cai YR; Wen FC; Zhang D; Bai YZ; Zhang XY; Wang SY; Cheng L; Zhong H; Liu L; Wang J; Han BH
    BMC Med; 2022 May; 20(1):170. PubMed ID: 35509036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients.
    Mazzaschi G; Minari R; Zecca A; Cavazzoni A; Ferri V; Mori C; Squadrilli A; Bordi P; Buti S; Bersanelli M; Leonetti A; Cosenza A; Ferri L; Rapacchi E; Missale G; Petronini PG; Quaini F; Tiseo M
    Lung Cancer; 2020 Oct; 148():1-11. PubMed ID: 32768804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC.
    Sun Y; Duan J; Fang W; Wang Z; Du X; Wang X; Li C; Cai S; Zhao J; Li S; Zhang L; Bai H; Wang J
    BMC Med; 2021 Oct; 19(1):239. PubMed ID: 34615542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential predictive value of change in inflammatory cytokines levels subsequent to initiation of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer.
    Lim JU; Yoon HK
    Cytokine; 2021 Feb; 138():155363. PubMed ID: 33264749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma.
    Li L; Lu G; Liu Y; Gong L; Zheng X; Zheng H; Gu W; Yang L
    Front Oncol; 2021; 11():658690. PubMed ID: 34150625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
    Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
    Front Immunol; 2021; 12():646874. PubMed ID: 33927719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review.
    Indini A; Rijavec E; Grossi F
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33918661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma Biomarkers and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: New Tools for Better Patient Selection?
    Costantini A; Takam Kamga P; Dumenil C; Chinet T; Emile JF; Giroux Leprieur E
    Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31470546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging Blood-Based Biomarkers for Predicting Response to Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer.
    Li S; Zhang C; Pang G; Wang P
    Front Immunol; 2020; 11():603157. PubMed ID: 33178229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer.
    Zhu C; Zhuang W; Chen L; Yang W; Ou WB
    Transl Lung Cancer Res; 2020 Feb; 9(1):111-138. PubMed ID: 32206559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC.
    Goh KY; Cheng TY; Tham SC; Lim DW
    Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maximum Somatic Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden Predicts the Efficacy of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer.
    Dong Y; Zhu Y; Zhuo M; Chen X; Xie Y; Duan J; Bai H; Hao S; Yu Z; Yi Y; Guan Y; Yuan J; Xia X; Yi X; Wang J; Wang Z
    Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypic and Proteomic Analysis Identifies Hallmarks of Blood Circulating Extracellular Vesicles in NSCLC Responders to Immune Checkpoint Inhibitors.
    Brocco D; Lanuti P; Pieragostino D; Cufaro MC; Simeone P; Bologna G; Di Marino P; De Tursi M; Grassadonia A; Irtelli L; De Lellis L; Veschi S; Florio R; Federici L; Marchisio M; Miscia S; Cama A; Tinari N; Del Boccio P
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33546102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Ba H; Liu L; Peng Q; Chen J; Zhu YD
    BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.